Os09g0247700 Antibody

What is Os09g0247700 Antibody and what target protein does it recognize?

Os09g0247700 Antibody (catalog number CSB-PA495729XA01OFG) is a research-grade antibody specifically designed to target the Auxin transport protein BIG in Oryza sativa subsp. japonica (Rice) . This protein is encoded by the Os09g0247700 gene (also referenced as LOC_Os09g07294) and carries the UniProt accession number B9G2A8 . The BIG protein plays a crucial role in auxin hormone transport mechanisms, which regulate numerous developmental processes in rice.

Unlike antibodies designed for clinical applications, such as the anti-Gn glycoprotein antibody (Ab10) used in severe fever with thrombocytopenia syndrome research, Os09g0247700 Antibody is optimized for plant protein detection in research settings . The commercially available antibody is typically supplied in two standard volumes: 2ml and 0.1ml preparations .

What validation methods should be employed to confirm Os09g0247700 Antibody specificity?

Confirming antibody specificity is essential for reliable experimental outcomes. For Os09g0247700 Antibody, researchers should implement a systematic validation approach:

• Western blot analysis must demonstrate a single band at the expected molecular weight of the auxin transport protein BIG (~450 kDa).

• Employ parallel testing with:

  • Positive controls: Wild-type rice tissues expressing BIG protein

  • Negative controls: BIG-knockout rice variants or non-plant tissues

• Pre-absorption testing should be conducted by incubating the antibody with purified recombinant BIG protein prior to immunoassays. Signal elimination indicates specificity.

• Cross-reactivity assessment against other rice proteins should be performed, similar to methodologies used for validating therapeutic antibodies like Ab10, which underwent extensive epitope mapping to determine binding specificity .

• Mass spectrometry validation of immunoprecipitated proteins can provide definitive confirmation of antibody target specificity.

What are the optimal storage and handling conditions for Os09g0247700 Antibody?

Proper storage and handling are critical for maintaining antibody functionality. Based on standard practices for research antibodies, Os09g0247700 Antibody requires:

These guidelines parallel those for therapeutic-grade antibodies such as the OKT3 monoclonal antibody, which specifies filtered (0.2 μm), endotoxin-free (<0.001 ng/μg) preparations for optimal performance .

How should experimental protocols be designed when using Os09g0247700 Antibody for western blotting?

Western blotting with Os09g0247700 Antibody requires specific protocol modifications for optimal detection of plant proteins:

• Sample preparation must include:

  • Plant-specific extraction buffers containing 100 mM Tris-HCl (pH 8.0), 150 mM NaCl, 5 mM EDTA

  • Plant protease inhibitor cocktail to prevent degradation

  • Reducing agents (10 mM DTT) to maintain protein conformation

• Gel electrophoresis considerations:

  • Use gradient gels (4-12%) for optimal separation of the high molecular weight BIG protein

  • Load appropriate positive controls from wild-type rice

• Transfer and detection optimization:

  • Extended transfer times (overnight at 30V) for complete transfer of large proteins

  • Recommended primary antibody dilution range: 1:500-1:2000

  • Incubation period: 16 hours at 4°C for maximum sensitivity

• Signal detection strategies:

  • Enhanced chemiluminescence provides optimal sensitivity

  • Quantification using densitometry with normalization to housekeeping proteins

This methodological approach draws on principles similar to those used in therapeutic antibody development, where optimized protocols are essential for reliable detection .

How can Os09g0247700 Antibody be integrated with other techniques to study auxin transport mechanisms?

Multi-technique approaches significantly enhance research outcomes. Os09g0247700 Antibody can be integrated with:

• Immunolocalization studies:

  • Use Os09g0247700 Antibody with fluorescent secondary antibodies for confocal microscopy

  • Combine with auxin-responsive reporter constructs (DR5-GFP) to correlate BIG protein localization with auxin activity

  • Implement dual immunolabeling with PIN protein antibodies to examine co-localization with auxin transporters

• Protein-protein interaction analysis:

  • Employ Os09g0247700 Antibody for co-immunoprecipitation followed by mass spectrometry

  • Validate interactions using yeast two-hybrid or BiFC assays

  • Map interaction domains through deletion constructs

• Genetic and molecular biology integration:

  • Compare protein expression (detected by Os09g0247700 Antibody) with gene expression data

  • Evaluate BIG protein levels in CRISPR/Cas9-generated mutants

  • Analyze post-translational modifications using phospho-specific antibodies

This integrated approach parallels advanced methodologies used in therapeutic antibody research, such as those employed to characterize the conformational epitopes of antibodies like Ab10 .

What are common challenges when using Os09g0247700 Antibody and how can they be resolved?

Researchers frequently encounter several challenges when working with plant antibodies:

These troubleshooting approaches are similar to those employed in therapeutic antibody development, where rigorous optimization is required to achieve reliable results .

How should immunoprecipitation protocols be optimized for Os09g0247700 Antibody?

Effective immunoprecipitation (IP) of the auxin transport protein BIG requires carefully optimized protocols:

• Lysis buffer composition must be tailored for plant membrane proteins:

  • 50 mM Tris-HCl (pH 7.5), 150 mM NaCl

  • 1% NP-40 or 0.5% Triton X-100

  • 10% glycerol to stabilize protein complexes

  • Plant protease inhibitor cocktail

• Pre-clearing strategy to reduce non-specific binding:

  • Incubate lysate with protein A/G beads without antibody (1 hour at 4°C)

  • Remove beads by centrifugation before adding Os09g0247700 Antibody

• Antibody binding optimization:

  • Use 2-5 μg antibody per 1 mg total protein

  • Incubate overnight at 4°C with gentle rotation

  • Consider crosslinking antibody to beads to prevent co-elution

• Washing conditions must balance removal of non-specific proteins while maintaining interactions:

  • Start with 3-5 washes in lysis buffer

  • Follow with 2 washes in higher stringency buffer (300 mM NaCl)

  • Final wash in low-salt buffer (50 mM Tris-HCl, pH 7.5)

• Elution and analysis optimization:

  • Elute with 0.1 M glycine (pH 2.5) for native conditions

  • Analyze by western blot and mass spectrometry

This methodological approach draws on principles used in therapeutic antibody research, where optimized immunoprecipitation protocols are essential for characterizing antibody-antigen interactions .

How can Os09g0247700 Antibody be applied to study post-translational modifications of the BIG protein?

Investigating post-translational modifications (PTMs) of auxin transport protein BIG requires specialized approaches:

• Phosphorylation analysis:

  • Use phosphatase inhibitors (50 mM NaF, 10 mM Na₃VO₄) in extraction buffers

  • Immunoprecipitate with Os09g0247700 Antibody

  • Analyze by western blot with phospho-specific antibodies

  • Confirm by mass spectrometry using neutral loss scanning

• Ubiquitination detection:

  • Add deubiquitinase inhibitors (10 mM N-ethylmaleimide) to lysis buffers

  • Perform sequential immunoprecipitation with Os09g0247700 Antibody followed by anti-ubiquitin antibody

  • Analyze modification sites by mass spectrometry

• Glycosylation analysis:

  • Treat immunoprecipitated BIG protein with glycosidases

  • Compare mobility shifts by western blotting

  • Use lectin affinity chromatography combined with Os09g0247700 immunodetection

• PTM dynamics during auxin response:

  • Time-course experiments after auxin treatment

  • Quantify changes in PTM levels by quantitative western blotting

  • Correlate modifications with protein activity and localization

These advanced analytical approaches parallel methodologies used in therapeutic antibody research, where detailed characterization of antibody-antigen interactions is essential .

What considerations apply when using Os09g0247700 Antibody in different rice varieties or related plant species?

Cross-species and cross-variety applications require careful consideration of protein conservation:

• Sequence homology analysis is essential:

  • Compare BIG protein sequences across target species/varieties

  • Focus particularly on the epitope region recognized by Os09g0247700 Antibody

  • Predict potential cross-reactivity based on amino acid conservation

• Experimental validation in each new species/variety must include:

  • Western blot with positive controls from japonica rice

  • Immunoprecipitation followed by mass spectrometry confirmation

  • Side-by-side comparison with known positive samples

• Protocol modifications for cross-species applications:

  • Extraction buffer optimization for different tissue compositions

  • Antibody concentration adjustments (typically 1.5-2× higher)

  • Extended incubation times for weaker interactions

This cross-species application approach draws on principles similar to those used in therapeutic antibody development, where antibody cross-reactivity must be carefully characterized .

How can Os09g0247700 Antibody contribute to understanding the role of BIG protein in plant stress responses?

Investigating stress responses requires specialized experimental designs:

• Experimental setup for stress studies:

  • Design time-course experiments with appropriate stress treatments (drought, salt, temperature)

  • Include controls for each stress condition and time point

  • Standardize tissue collection and processing protocols

• Protein expression analysis:

  • Quantify BIG protein levels using Os09g0247700 Antibody by western blotting

  • Normalize to appropriate housekeeping proteins

  • Compare protein levels with mRNA expression data

• Protein localization during stress:

  • Use immunohistochemistry with Os09g0247700 Antibody to track changes in BIG protein localization

  • Combine with subcellular markers to monitor trafficking

  • Quantify redistribution using digital image analysis

• Protein-protein interaction dynamics:

  • Perform co-immunoprecipitation under stress conditions

  • Identify stress-specific interaction partners

  • Map domains involved in stress-responsive interactions

This methodological approach parallels strategies used in therapeutic antibody research, where detailed characterization of antibody behavior under various conditions is essential for development of effective treatments .

What emerging technologies can enhance research applications of Os09g0247700 Antibody?

Several cutting-edge technologies offer potential to advance research with Os09g0247700 Antibody:

• Super-resolution microscopy techniques:

  • STORM and PALM imaging with Os09g0247700 Antibody can reveal nanoscale localization of BIG protein

  • Multi-color super-resolution permits co-localization studies with auxin transporters

  • Live-cell super-resolution enables dynamic studies of BIG protein trafficking

• Proximity labeling approaches:

  • BioID or APEX2 fusion to BIG protein can map protein neighborhoods

  • Os09g0247700 Antibody validates proximity labeling results

  • Enables temporal mapping of protein interaction networks

• Single-cell analysis technologies:

  • Combine Os09g0247700 Antibody with cell sorting techniques

  • Analyze cell-type specific BIG protein expression patterns

  • Correlate with single-cell transcriptomics data

• Cryo-electron microscopy:

  • Use Os09g0247700 Antibody to purify BIG protein complexes

  • Determine structural arrangements at near-atomic resolution

  • Identify conformational changes upon auxin binding

These advanced technologies parallel emerging approaches in therapeutic antibody development, such as the structural characterization of antibody-antigen complexes to determine epitope binding properties .

How might comparative studies with antibodies targeting different epitopes of BIG protein advance our understanding?

Developing and utilizing multiple antibodies against different BIG protein epitopes offers several research advantages:

• Epitope mapping considerations:

  • Generate antibodies against N-terminal, central, and C-terminal domains

  • Compare detection efficiency across different experimental conditions

  • Identify accessible epitopes in native versus denatured states

• Functional domain analysis:

  • Use domain-specific antibodies to track conformational changes

  • Correlate with functional states of the protein

  • Identify regulatory domains through differential accessibility

• Therapeutic antibody development approaches can inform strategy:

  • Similar to the Ab10 antibody, which binds to a conformational epitope spanning domain II and stem region of viral Gn glycoprotein

  • Conformational epitopes often provide insights into protein function

• Comparative assay development:

  • Sandwich ELISA using different epitope-targeting antibodies

  • Competition assays to identify conformational states

  • Multiplex imaging with differently labeled epitope-specific antibodies

This multi-epitope strategy draws on approaches used in therapeutic antibody development, where understanding epitope location and accessibility is crucial for developing effective antibodies .